Ann: Publication of Invex IIH Phase II Pressure Trial Results, page-7

The Phase III raise encompassed the costs for a go-it-alone reformulation strategy, with Bell Potter suggesting in a Q&A with IXC that they saved $5-6M in going with Peptron for their reformulation supply/manufacturing, alongside 12 months in time.

I would wager that the above, alongside the existing Phase III contingency baked into the last $26M raise will be enough for early work streams for Phase II work (and with Biotech timelines, a phase II trial wont be ready until 2025 when a Phase III read out is to occur anyway, where CR will be far cheaper than where we are today).